Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic HER2-positive breast cancer. The combination…

Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsbreastca/116216

Author :

Publish date : 2025-06-24 15:23:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

Simpler Lung Cancer Screening Criteria May Still Maintain Diagnostic Efficiency

How Fast Is Too Fast for FDA Drug Review?

Related Posts

Blood Test Detects ALS Years Before Symptom Onset

Separating Fact From Fiction in ‘Mini IVF’

GOP Sen. Cassidy, Facing Primary Challengers, Proceeds Cautiously on CDC and RFK Jr.

Multiple Medical Societies Demand RFK Jr.’s Resignation

Why Does Smoking Help UC but Hurt CD?

$1B Malpractice Award; Hospital CMO’s Husband Detained; Doc Gets 40 Years

Blood Test Detects ALS Years Before Symptom Onset

Separating Fact From Fiction in ‘Mini IVF’

GOP Sen. Cassidy, Facing Primary Challengers, Proceeds Cautiously on CDC and RFK Jr.

Multiple Medical Societies Demand RFK Jr.’s Resignation

Why Does Smoking Help UC but Hurt CD?

$1B Malpractice Award; Hospital CMO’s Husband Detained; Doc Gets 40 Years

Surgeon Neil Hopper admits fraud over amputation of own legs

Martha’s Rule Rolled Out Across NHS England Hospitals

Categories

Archives